Bayesian modeling improves drug responses in multi-state systems, suggesting enhanced preclinical drug assessment.
Understanding drug responses at the cellular level is essential for elucidating mechanisms of action and advancing preclinical drug development. Traditional dose-response models rely on simplified metrics, limiting their ability to quantify parameters like cell division, death, and transition rates between cell states. To address these limitations, we developed Bayesian Estimation of STochastic processes for Dose-Response (BESTDR), a framework modeling cell growth and treatment response dynamics to estimate concentration-response relationships using longitudinal cell count data. BESTDR enabled quantification of rates in multi-state systems across multiple cell lines using hierarchical modeling to support high-throughput screening. Validation of BESTDR with synthetic and experimental datasets demonstrated its robustness and accuracy in estimating drug response. By integrating mechanistic modeling of cytotoxic, cytostatic, and other effects, BESTDR enhances dose-response studies, facilitating robust drug comparisons and mechanism-specific analyses. BESTDR offers a versatile tool for early-stage preclinical research, paving the way for drug discovery and informed experimental design.
No takes yet. Share an insight, caveat, or question.
McDonald et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: